drugset / Trial / NCT00035971

EVA: Evista Alendronate Comparison

NCT00035971

Phase 4 Completed Eli Lilly and Company
Treatment

Summary

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 10 mg
Subject Raloxifene Other / unclassified 60 mg

Indications